Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis - Concepedia

Concepedia

Publication | Open Access

Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis

DOI Full Paper Access

40

Citations

35

References

2008

Year

Kristen Picha, Mark R. Cunningham, Daniel J. Drucker, Ashok Mathur, Tatiana Ort, Michael S. Scully, Avery R. Soderman, Tracy Spinka-Doms, V. Stojanovic‐Susulic, Beth Ann Thomas,

Abstract

Taken together, our data demonstrate that CNTO736 produces a spectrum of GLP-1 receptor-dependent actions while exhibiting significantly improved pharmacokinetics relative to the native GLP-1 peptide.

References

	Year	Citations
A role for glucagon-like peptide-1 in the central regulation of feeding Mandy D. Turton, Donal O’Shea, I. Gunn, Nature NutritionEnergy HomeostasisGastrointestinal Peptide HormoneSignal TransductionPhysiology	1996	1.9K
GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams, The Lancet Molecular PhysiologyPhysiologyGlucagon-like Peptide-1 7-36EndocrinologyMedicine	1987	1.9K
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes Ralph A. DeFronzo, Robert E. Ratner, Jenny Han, Diabetes Care	2005	1.5K
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes John B. Buse, Robert R. Henry, Jenny Han, Diabetes Care	2004	1.3K
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study Mette Zander, Sten Madsbad, Jan Lysgaard Madsen, The Lancet Metabolic SyndromeDiabetes ManagementGlucagon-like Peptide 1DiabetesPhysiology	2002	1.3K
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea David M. Kendall, Matthew C. Riddle, Julio Rosenstock, Diabetes Care	2005	1.2K
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Timothy J. Kieffer, Christopher H.S. McIntosh, Raymond A. Pederson Endocrinology GlycobiologyPeptide SciencePeptide ChemistryInsulin SignalingIncubation Mixture	1995	1.1K
Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Daniel J. Drucker, Jan Philippé, Svetlana Mojsov, Proceedings of the National Academy of Sciences Glucagon-like PeptideCyclic Amp LevelsCellular PhysiologyInsulin SignalingGastrointestinal Peptide Hormone	1987	873
Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene Louise A. Scrocchi, Theodore J. Brown, Neil J. MacLusky, Nature Medicine Metabolic SyndromeInsulin SignalingSignal TransductionG Protein-coupled ReceptorInsulin Management	1996	788
Monoclonal antibody successes in the clinic Janice M. Reichert, Clark Rosensweig, Laura Faden, Nature Biotechnology Autoimmune DiseaseImmunologyAntibody ScreeningAutoimmunityAutoantibodies	2005	725

Page 1